JP2018506585A5 - - Google Patents

Download PDF

Info

Publication number
JP2018506585A5
JP2018506585A5 JP2017560479A JP2017560479A JP2018506585A5 JP 2018506585 A5 JP2018506585 A5 JP 2018506585A5 JP 2017560479 A JP2017560479 A JP 2017560479A JP 2017560479 A JP2017560479 A JP 2017560479A JP 2018506585 A5 JP2018506585 A5 JP 2018506585A5
Authority
JP
Japan
Prior art keywords
raav
nucleic acid
disease
raav particle
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017560479A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018506585A (ja
JP6928558B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/017210 external-priority patent/WO2016130591A2/en
Publication of JP2018506585A publication Critical patent/JP2018506585A/ja
Publication of JP2018506585A5 publication Critical patent/JP2018506585A5/ja
Priority to JP2021129519A priority Critical patent/JP2021178861A/ja
Application granted granted Critical
Publication of JP6928558B2 publication Critical patent/JP6928558B2/ja
Priority to JP2023018846A priority patent/JP2023058630A/ja
Priority to JP2024228114A priority patent/JP2025060823A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017560479A 2015-02-10 2016-02-09 線条体および皮質へのウイルス粒子の強化された送達 Active JP6928558B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021129519A JP2021178861A (ja) 2015-02-10 2021-08-06 線条体および皮質へのウイルス粒子の強化された送達
JP2023018846A JP2023058630A (ja) 2015-02-10 2023-02-10 線条体および皮質へのウイルス粒子の強化された送達
JP2024228114A JP2025060823A (ja) 2015-02-10 2024-12-25 線条体および皮質へのウイルス粒子の強化された送達

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562114544P 2015-02-10 2015-02-10
US62/114,544 2015-02-10
US201562220997P 2015-09-19 2015-09-19
US62/220,997 2015-09-19
PCT/US2016/017210 WO2016130591A2 (en) 2015-02-10 2016-02-09 Enhanced delivery of viral particles to the striatum and cortex

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021129519A Division JP2021178861A (ja) 2015-02-10 2021-08-06 線条体および皮質へのウイルス粒子の強化された送達

Publications (3)

Publication Number Publication Date
JP2018506585A JP2018506585A (ja) 2018-03-08
JP2018506585A5 true JP2018506585A5 (https=) 2019-03-22
JP6928558B2 JP6928558B2 (ja) 2021-09-01

Family

ID=56614902

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017560479A Active JP6928558B2 (ja) 2015-02-10 2016-02-09 線条体および皮質へのウイルス粒子の強化された送達
JP2021129519A Pending JP2021178861A (ja) 2015-02-10 2021-08-06 線条体および皮質へのウイルス粒子の強化された送達
JP2023018846A Pending JP2023058630A (ja) 2015-02-10 2023-02-10 線条体および皮質へのウイルス粒子の強化された送達
JP2024228114A Pending JP2025060823A (ja) 2015-02-10 2024-12-25 線条体および皮質へのウイルス粒子の強化された送達

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021129519A Pending JP2021178861A (ja) 2015-02-10 2021-08-06 線条体および皮質へのウイルス粒子の強化された送達
JP2023018846A Pending JP2023058630A (ja) 2015-02-10 2023-02-10 線条体および皮質へのウイルス粒子の強化された送達
JP2024228114A Pending JP2025060823A (ja) 2015-02-10 2024-12-25 線条体および皮質へのウイルス粒子の強化された送達

Country Status (27)

Country Link
US (3) US20190111157A1 (https=)
EP (3) EP4023758A1 (https=)
JP (4) JP6928558B2 (https=)
KR (2) KR102625784B1 (https=)
CN (2) CN116019934A (https=)
AU (3) AU2016219398A1 (https=)
BR (1) BR112017017037A2 (https=)
CA (1) CA2976082A1 (https=)
CL (1) CL2017002028A1 (https=)
CR (1) CR20170407A (https=)
DK (1) DK3256594T3 (https=)
EA (1) EA201791803A1 (https=)
ES (1) ES2904504T3 (https=)
HU (1) HUE057272T2 (https=)
IL (4) IL313840A (https=)
LT (1) LT3256594T (https=)
MX (2) MX388264B (https=)
NZ (1) NZ772772A (https=)
PH (1) PH12017501436A1 (https=)
PL (1) PL3256594T3 (https=)
PT (1) PT3256594T (https=)
RS (1) RS62811B1 (https=)
SG (3) SG10201907399RA (https=)
SI (1) SI3256594T1 (https=)
TN (1) TN2017000353A1 (https=)
TW (1) TWI730952B (https=)
WO (1) WO2016130591A2 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
CA3193811A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN119876138A (zh) 2014-11-14 2025-04-25 沃雅戈治疗公司 调节性多核苷酸
HK1245326A1 (zh) 2014-12-12 2018-08-24 Voyager Therapeutics, Inc. 用於生产scaav的组合物和方法
TN2017000353A1 (en) * 2015-02-10 2019-01-16 Genzyme Corp Enhanced delivery of viral particles to the striatum and cortex
TWI707951B (zh) 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造
CA3019315A1 (en) 2015-04-23 2016-10-27 University Of Massachusetts Modulation of aav vector transgene expression
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
RU2742352C2 (ru) 2015-09-24 2021-02-05 Байомарин Фармасьютикал Инк. Векторы фактора fviii на основе аденоассоциированных вирусов, соответствующие вирусные частицы и содержащие их терапевтические композиции
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
CA3024448C (en) 2016-05-18 2025-09-09 Voyager Therapeutics, Inc. MODULATING POLYNUCLEOTIDES
CA3024449A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
JP7059285B2 (ja) * 2016-09-30 2022-04-25 エステベ プアルマセウティカルス， エッセ．ア． ムコ多糖症の治療のためのアデノ随伴ウイルスベクター
EP3613856A4 (en) * 2017-03-31 2020-12-23 Staidson(Beijing) Biopharmaceuticals Co., Ltd. SHORT RNA EXPRESSION CASSETTE IN HAIRPIN, POLYNUCLEOTIDIAL SEQUENCE WEARING IT AND CORRESPONDING APPLICATION
WO2018191450A2 (en) 2017-04-14 2018-10-18 National Taiwan University Hospital Gene therapy for aadc deficiency
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
JP2020518259A (ja) * 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
JP7221275B2 (ja) 2017-08-03 2023-02-13 ボイジャー セラピューティクス インコーポレイテッド Ａａｖを送達するための組成物および方法
US20200263199A1 (en) 2017-09-29 2020-08-20 Voyager Therapeutics, Inc. Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
BR112020020836A2 (pt) 2018-04-13 2021-01-19 University Of Massachusetts Vetores de aav bicistrônicos codificando subunidades alfa e beta de hexosaminidase e usos dos mesmos
SG11202011296VA (en) 2018-05-15 2020-12-30 Voyager Therapeutics Inc Compositions and methods for the treatment of parkinson's disease
CN113528510A (zh) * 2018-06-29 2021-10-22 武汉纽福斯生物科技有限公司 治疗遗传性视神经病变的组合物和方法
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
US12448629B2 (en) 2018-10-05 2025-10-21 University Of Massachusetts rAAV vectors for the treatment of GM1 and GM2 gangliosidosis
EP3880235A4 (en) * 2018-11-14 2022-08-10 REGENXBIO Inc. GENE THERAPY OF NEURAL ZEROID LIPOFUSCINOSES
BR112021015817A2 (pt) * 2019-02-22 2021-10-13 The Trustees Of The University Of Pennsylvania Vírus adeno-associado recombinante para tratamento de neurodegeneração com início na idade adulta associado a grn
US20220307024A1 (en) * 2019-06-17 2022-09-29 Alnylam Pharmaceuticals, Inc. Delivery of oligonucleotides to the striatum
WO2021007382A1 (en) * 2019-07-09 2021-01-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
US20220275367A1 (en) * 2019-07-24 2022-09-01 Voyager Therapeutics, Inc. Compositions and methods for treating huntington's disease
WO2021177116A1 (ja) * 2020-03-02 2021-09-10 国立大学法人群馬大学 ミクログリア選択的遺伝子発現ベクター
JP2023517230A (ja) * 2020-03-11 2023-04-24 リモーター セラピューティクス インコーポレイテッド 中枢神経系全体にわたってタンパク質を散在させるための方法および材料
CN116171166A (zh) * 2020-06-30 2023-05-26 塞其里斯英国有限公司 水包油乳液佐剂的冷过滤
JP2024505885A (ja) * 2021-01-27 2024-02-08 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル リソソーム酸リパーゼ欠損症（ｌａｌ－ｄ）の治療のための材料及び方法
US20230034817A1 (en) 2021-04-12 2023-02-02 Affinia Therapeutics Inc. Recombinant aav for treatment of neural disease
WO2023113806A1 (en) 2021-12-16 2023-06-22 Affinia Therapeutics, Inc. Recombinant aav for treatment of neural disease
WO2023108507A1 (en) * 2021-12-15 2023-06-22 National Institute Of Biological Sciences, Beijing Recombinant aav vectors and use thereof
US20250333758A1 (en) * 2021-12-15 2025-10-30 Genans Biotechnology Co., Ltd Microglia having car and use thereof
EP4499155A4 (en) * 2022-03-25 2026-04-01 Askbio Inc METHODS AND COMPOSITIONS INTENDED FOR THE TREATMENT OF PARKINSON'S DISEASE
WO2024086747A1 (en) 2022-10-19 2024-04-25 Affinia Therapeutics Inc. Recombinant aavs with improved tropism and specificity
WO2025151454A1 (en) * 2024-01-08 2025-07-17 AskBio Inc. Method or system of infusing and/or predicting an infusate volume
WO2025227063A1 (en) 2024-04-26 2025-10-30 Affinia Therapeutics Inc. Recombinant aavs with improved tropism and specificity

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US5735815A (en) 1993-07-26 1998-04-07 Sentinel Medical, Inc. Method of using fluid jet surgical cutting tool
AU722624B2 (en) 1996-09-06 2000-08-10 Trustees Of The University Of Pennsylvania, The An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
US6042579A (en) 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
DE69929600T2 (de) 1998-05-27 2006-09-07 Avigen Inc., Alameda Konvektion-erhöhte verabreichung aadc-kodierende aav vektoren
PT1916258E (pt) 1999-08-09 2014-07-29 Genzyme Corp Aumento da expressão de uma sequência nucleotídica heteróloga de cadeia simples a partir de vectores virais recombinantes por concepção da sequência de maneira que esta forme pares de bases intracadeia
NZ522840A (en) 2000-06-01 2004-12-24 Univ North Carolina A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together
WO2003004660A1 (en) 2001-07-03 2003-01-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods of administering vectors to synaptically connected neurons
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
NZ532635A (en) 2001-11-13 2007-05-31 Univ Pennsylvania A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method
GB2389791B (en) 2002-04-30 2006-12-13 Steven Gill Implantable drug delivery pump
DE602004030327D1 (de) 2003-05-21 2011-01-13 Genzyme Corp Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind
PT1807009E (pt) 2004-10-05 2015-02-25 Univ California Cânula escalonada
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
EP1879624B1 (en) 2005-05-02 2011-09-21 Genzyme Corporation Gene therapy for neurometabolic disorders
AU2006283189B2 (en) 2005-08-23 2013-01-31 The Regents Of The University Of California Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
WO2007127803A2 (en) 2006-04-25 2007-11-08 The Regents Of The University Of California Administration of growth factors for the treatment of cns disorders
US20070259031A1 (en) 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
WO2008144585A1 (en) 2007-05-17 2008-11-27 Medgenesis Therapeutix Inc. Convection-enhanced delivery catheter with removable stiffening member and method for using same
BRPI1007155A2 (pt) 2009-01-29 2017-05-30 Univ Of California San Francisco métodos para tratar um distúrbio neurológico cortical, e para dispensar um agente terapêutico para o córtex em um primata
HUE028341T2 (en) 2009-06-16 2016-12-28 Genzyme Corp Improved methods for purification of recombinant aav vectors
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
ES2739804T3 (es) * 2011-02-12 2020-02-04 Univ Iowa Res Found Compuestos terapéuticos
DK2675902T3 (da) 2011-02-17 2019-06-03 Univ Pennsylvania Sammensætninger og fremgangsmåder til at ændre vævsspecificitet og forbedre aav9-medieret genoverførsel
IL248102B (en) * 2014-05-02 2022-07-01 Genzyme Corp aav vectors for gene therapy of the central nervous system and retina
TN2017000353A1 (en) * 2015-02-10 2019-01-16 Genzyme Corp Enhanced delivery of viral particles to the striatum and cortex
CN111417231A (zh) 2019-01-04 2020-07-14 青岛海尔股份有限公司 电磁波发生系统及具有该电磁波发生系统的加热装置

Similar Documents

Publication Publication Date Title
JP2018506585A5 (https=)
JP7698583B2 (ja) 組換えアデノ随伴ウイルスベクター
JP7574508B2 (ja) 血管系を通過する遺伝子移入の方法および組成物
US12465657B2 (en) Enhanced delivery of viral particles to the striatum and cortex
JP7425738B2 (ja) 眼組織を標的とするウイルスベクター
JP7385282B2 (ja) 環状ｒｎａ分子のための方法及び組成物
US9447433B2 (en) Synthetic adeno-associated virus inverted terminal repeats
JP2024016041A (ja) 抗体を回避するウイルスベクター
EP3245220B1 (en) Methods and compositions for targeted gene transfer
JP2014507145A (ja) 改変された形質導入プロファイルを有するウイルスベクターならびにその製造および使用の方法
CN116478254A (zh) 增强细小病毒载体递送的修饰衣壳蛋白
JP2018500904A (ja) ウィルソン病の処置に使用するための核酸構築物及び遺伝子治療ベクター
JP2016503405A5 (https=)
CN114787180A (zh) 用于治疗c型尼曼-匹克病的腺相关病毒载体
US20220298528A1 (en) Viral particles for use in treating synucleinopathies such as parkinson's diseases by gene therapy
US20230277687A1 (en) Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy
HRP20220042T1 (hr) Poboljšana isporuka virusnih čestica u strijatum i korteks
US12605465B2 (en) AAV-NAGLU vectors for treatment of mucopolysaccharidosis IIIB
CN114746556A (zh) 用于治疗山菲立普病和其他障碍的组合物和方法
Broekman Discussion and conclusion